Eptinezumab Biologics License Application Accepted by the FDA for Review
The FDA has accepted for review the Biologics License Application for eptinezumab (Alder BioPharmaceuticals), an investigational CGRP inhibitor for migraine prevention.
Uncategorized
Fat Injection Safe and Effective as Migraine Headache Treatment
Investigators found that using a fat injection technique to treat patients with migraine headache using small divisions over an array into nerves identified as migraine triggers, such as the trigeminal and cervical nerve branches, was successful in the majority of patients treated.
Reconsidering Lidocaine as an Acute Treatment for Headache
Researchers found that intranasal lidocaine is effective in the treatment of acute migraine and cluster headache because of its ability to block the sphenopalatine ganglion, which is associated with facial pain from the trigeminal nerve.
Updated Guidelines for Controlled Trials of Acute Treatment of Migraine
New guidelines from the International Headache Society aim to affect the design, conduct, and reporting for clinical trials in migraine.
AMA Code of Medical Ethics: Guidelines for Immigrant Patient Care
The AMA Code of Medical Ethics offers guidance on how physicians and healthcare systems can best support undocumented and lawfully present immigrants to promote the best possible care for all who need it.
Clinical Outcomes Compared With Generics, Brand-Name Drugs for Chronic Conditions
An analysis of data from over 3.5 million patients found comparable clinical outcomes among patients who initiated generics vs those who were treated with brand-name drugs for chronic conditions such as diabetes, hypertension, osteoporosis, depression and anxiety.
Pharmacist-Led Phone Follow-Up May Cut Readmission Rates
A pharmacist-led, postdischarge structured telephone follow-up intervention can reduce 30-day and 90-day readmission rates for polypharmacy patients.
Practices Should Set Rules for Staff Social Media Use
Medical practices can take steps to avoid problems related to use of social media by staff members.
Ajovy Injection Approved for Migraine Prevention in Adults
The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.
In Migraine, Attachment Insecurity Linked to Anxiety
Anxiety in children and adolescents with migraine without aura may be amplified by attachment insecurity.
Want to read more?
Please login or register first to view this content.